Previous 10 | Next 10 |
WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGM...
WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 f...
Gainers: Five Prime Therapeutics (NASDAQ: FPRX ) +19% . Ocugen (NASDAQ: OCGN ) +19% . Navios Maritime Holdings (NYSE: NM ) +16% . RISE Education Cayman (NASDAQ: REDU ) +15% . The National Security Group (NASDAQ: NSEC ) +15% . Catabasis Pharmaceuticals (NASDAQ: CATB ) +15% . ele...
Syndax Pharmaceuticals ( SNDX -0.6% ) announces the fifth and final successful interim futility analysis of survival data in the Cancer Research Group-sponsored Phase 3 clinical trial, E2112 , evaluating the combination of lead drug entinostat and exemestane (Pfizer's Aromasin) in patie...
WALTHAM, Mass. , Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participa...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. In...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2019 Earnings Conference Call August 07, 2019 04:30 PM ET Company Participants Melissa Forst - Vice President, Argot Partners Briggs Morrison - Chief Executive Officer Rick Shea - Chief Financial Officer Michael Meyers - Chief Medical Offi...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...